TPO and hematocrit: 1. It has been shown that the rs7975232 polymorphism is not associated with susceptibility to HT and Graves’ disease. The AA genotype was observed more frequently in patients with HT and Graves’ disease under 40 years of age compared to those over 40 years of age with p-values of p = 0.02 and p = 0.03, respectively.2. The rs7975232 polymorphism is not associated with gender, age, or the presence or absence of anti-TPO and anti-Tg antibodies in patients with HT.3. VDR rs7975232 polymorphism may be a prognostic factor in predicting the severity of HT.